September 2012 Meeting Announcement, Delaware Valley Mass Spectrometry Discussion Group
PLEASE NOTE: We will meet in Mendel 154.
- Topic: "Drug Resistance and Pseudoresistance to Aspirin"
- Speaker:Tilo Grosser, University of Pennsylvania
- Date: Monday, September 10, 2012. 6:30 PM
- Time: Social Hour: 6:30 PM.
Talk: 7:30 PM.
Please RSVP to Eric Manning firstname.lastname@example.org by Thursday September 6th.
- Place: Department of Chemistry, Villanova University (Room 154, Mendel Hall)
Low dose aspirin reduces the secondary incidence of myocardial infarction and stroke. Drug resistance to aspirin might result in treatment failure. Despite this concern, no clear definition of “aspirin resistance” has emerged and estimates of its incidence have varied remarkably. Aspirin inhibits platelet cyclooxygenase (COX) -1 covalently by acetylatin a serine residue in the substrate binding channel. Thus, quantification of COX-1 acetylation might provide novel insight into mechanisms underlying "aspirin resistance". We developed a stable isotope dilution liquid chromatography multiple reaction monitoring/mass spectrometry (LC-MRM/MS) method for direct measurement of platelet COX-1 acetylation by aspirin. Biomarker qualification experiments in vitro, ex vivo and in vivo suggest that this is a robust assay which may have utility in clinical studies of aspirin non-responsiveness and perhaps therapeutic monitoring in patients.
Dr. Tilo Grosser received his MD degree and a doctorate in cardiovascular pharmacology from Heinrich-Heine University in Düsseldorf, Germany. He trained in medicine and cardiology in Germany and in pharmacology and experimental therapeutics at the University of Pennsylvania. He is currently a Research Assistant Professor of Pharmacology at the Institute for Translational Medicine and Therapeutics at Penn, where he studies the mechanisms of drug complications of nonsteroidal antiinflammatory drugs (NSAIDs) using genomics, proteomics, lipidomics approaches in model organisms and in proof-of-concept studies in volunteers. One aim of this research is to identify approaches to the personalization of NSAID therapy.
Please send any comments, corrections, or suggestions to
This page has been accessed
times since 9/15 /96 .
Last Updated 8/22/2012